SCHEMBL23211804

SCHEMBL23211804

Cc1cc(C2CN(C(=O)O)C2)ccc1OC(F)(F)F

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 2/20 0.37
PPARD Q03181 2/20 0.37
PPARA Q07869 2/20 0.37
HCRTR1 O43613 1/20 0.37
HCRTR2 O43614 1/20 0.37
USP30 Q70CQ3 1/20 0.37
TRPV1 Q8NER1 1/20 0.37
CHRM2 P08172 1/20 0.36
CHRM1 P11229 1/20 0.36
CHRM3 P20309 1/20 0.36
CSF1R P07333 1/20 0.36
SLC6A9 P48067 1/20 0.36
KCNH2 Q12809 1/20 0.36
PDE4B Q07343 5/20 0.36
DRD2 P14416 1/20 0.35
DRD1 P21728 1/20 0.35
DRD4 P21917 1/20 0.35
DRD5 P21918 1/20 0.35
DRD3 P35462 1/20 0.35
PROKR1 Q8TCW9 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23211938 0.85 EPHX2 (0.38) CSF1RSLC6A9KCNH2PDE4BMGLL
SCHEMBL23212022 0.85 EPHX2 (0.46) USP30CHRM2
SCHEMBL30567982 0.85 PDE4B (0.48) USP30PDE4B
SCHEMBL23211833 0.85 PDE4B (0.48) USP30PDE4B
SCHEMBL21381905 0.84 EPHX2 (0.39) TRPV1CSF1RSLC6A9KCNH2PDE4B
SCHEMBL23211917 0.84 KMO (0.42) HCRTR1HCRTR2DRD4MGLL
SCHEMBL23211911 0.81 CHRM4 (0.40) USP30CHRM2CHRM1CHRM3
SCHEMBL23212009 0.78 TP53 (0.46) USP30MGLL
SCHEMBL16951871 0.78 SSTR4 (0.40) PPARGPPARDPPARACHRM2CHRM1
SCHEMBL642891 0.76 F2R (0.45) CHRM2CHRM1CHRM3PDE4BMGLL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230117324-A1 OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2023-04-20 US disclosed
EP-3768684-B1 OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS HOFFMANN LA ROCHE (CH) 2023-02-22 EP disclosed
US-20210107920-A1 OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2021-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210107920-A1 OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS MGLL, LPL, LIPC PPARG 1687/4885PPARD 1236/4885PPARA 1135/4885
US-20230117324-A1 OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS MGLL, LPL, LIPC PPARG 1687/4885PPARD 1236/4885PPARA 1135/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.